Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Antares Therapeutics, Inc. is currently navigating the patent prosecution process with 1 pending office action. This action is being handled by 1 distinct examiner, AGGARWAL, SAHIL CHANDER. The data currently shows 0 distinct art units for this portfolio, which may indicate that the technical classification for the pending matter is in a transitional state or is highly specialized within the patent office's internal systems.
The busiest examiner for Antares Therapeutics, Inc. is AGGARWAL, SAHIL CHANDER, who is responsible for the 1 pending office action currently on record. As the sole examiner involved in the company's pending affairs, this individual has a significant influence over the immediate direction of the company's intellectual property strategy. Practitioners should prioritize a clear and direct line of communication with the assigned examiner to resolve the current matter effectively.
The presence of only 1 distinct examiner reflects a very focused and centralized prosecution profile. Without the involvement of multiple examiners or any recorded art units, the company's current efforts are concentrated on a single point of review. Future activity may see the company expand into various art units, but for now, the focus remains entirely on the interaction with AGGARWAL, SAHIL CHANDER regarding the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AGGARWAL, SAHIL CHANDER | 1 | 100.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18846616 | MULTICYCLIC COMPOUNDS | AGGARWAL, SAHIL CHANDER | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18846616 | MULTICYCLIC COMPOUNDS | AGGARWAL, SAHIL CHANDER | — | §102§103§112DP | Non-Final OA | — | Pending | Sep 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial